Company Overview
Kairos Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies designed to overcome drug resistance and immune suppression in cancer patients. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. By inhibiting CD105 on cancer cell surfaces, ENV105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in Phase 2 clinical trials for prostate cancer and Phase 1 trials for lung cancer, addressing significant unmet medical needs.
Investment Highlights
- Three ongoing clinical programs
⎼ Phase 2 trial treating Prostate Cancer with NIH grant funding
⎼ Phase 1 trial in treating Non-Small Cell Lung Cancer –Non-dilutive, Donor funded
⎼ Cleared IND for Glioblastoma - Strategic relationship with Cedars-Sinai Medical Center (ranked #2 hospital nationally in 2022-2023 US News and World Report) drives clinical trial efficiency (Costs and Enrollment), and streamlines therapeutic innovations
- Initial clinical development focuses on therapies to overcome cancer drug resistance, derisked with extensive safety studies and biomarker for potential response
- Extensive therapies to reverse immune suppression in our pipeline
- Extensive IP portfolio valid until 2035 to 2040
- Our technologies target a high value, large market - a fast growing $11.3 billion hormone therapy prostate cancer market, $14 billion lung cancer market, and $94 billion immunotherapy market
